RLM.L Regulatory News (RLM)

26 June 2013

PuriCore plc

 ("PuriCore" or the "Company")

PuriCore(LSE: PURI) today announces that Resolutions 1 to 13 were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's investor website at http://investor.puricore.com.

The resolutions will be available shortly for inspection at the National Storage Mechanism at www.hemscott.com/nsm.do.

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is an established global company focused on safely and effectively protecting people from the spread of infectious pathogens without causing harm to human health or the environment. PuriCore's products, services, and technologies are used principally in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. PuriCore also offers a breakthrough wound therapy solution to treat chronic and acute wounds including diabetic ulcers and burns as well as atopic dermatitis as dermatologic treatment products. In the Food & Agriculture market, Company's products are used to reduce fresh produce and floral inventory shrink and address cross contamination in three of the top-five leading US supermarket chains. In addition, the Company is progressing in its research and development programmes at Oxford University on the use of its technology as an agricultural fungicide.PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com, which does not form part of this announcement.